The Experts below are selected from a list of 489 Experts worldwide ranked by ideXlab platform

Hiroyuki Tsujimoto - One of the best experts on this subject based on the ideXlab platform.

  • The influences of a novel anti-adhesion device, thermally cross-linked gelatin film on peritoneal dissemination of tumor cells: The in vitro and in vivo experiments using murine Carcinomatous Peritonitis models.
    Journal of biomedical materials research. Part B Applied biomaterials, 2017
    Co-Authors: Hiroe Miyamoto, Hiroyuki Tsujimoto, Tsunehito Horii, Yuki Ozamoto, Joe Ueda, Toshitaka Takagi, Naoto Saitoh, Akeo Hagiwara
    Abstract:

    To create anti-adhesive materials to be more effective and safer, we developed a thermally cross-linked gelatin film that showed superior anti-adhesive effects with excellent peritoneal regeneration. However, it may act as a convenient scaffold for tumor cell growth, thereby accelerating peritoneal dissemination when used in surgery for abdominal tumors. In this study, we tried to clarify this issue using mouse Carcinomatous Peritonitis models. First, we examined the in vitro tumor cell growth of mouse B16 melanoma or Colon26 cells on the gelatin film or the conventional hyarulonate/carboxymethylcellulose film. Tumor cell growth on each film was significantly lower than that of the control (no film). Next, we conducted the following in vivo experiments: After the parietal peritoneum was partially removed and covered with each film or without any film, mice were inoculated intraperitoneally with B16 melanoma or Colon26/Nluc cells expressing NanoLuc luciferase gene. At 7 days after the operation, we measured the weight of B16 melanoma tumors or the NanoLuc activity of Colon26/Nluc cells using in vivo imaging at the injured sites. There were no significant differences in the weight of the tumors and the NanoLuc activity among the three groups. We also observed the survival time of mice receiving the same operation and treatments. There was no significant difference in the survival time among the three groups. These results suggest that the gelatin film will likely not accelerate peritoneal dissemination as a convenient scaffold for tumor cell growth when used in surgery for abdominal tumors. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 2122-2130, 2018.

  • Therapeutic effects of the angiogenesis inhibitor TNP-470 against Carcinomatous Peritonitis in mice.
    Anti-cancer drugs, 1995
    Co-Authors: Hiroyuki Tsujimoto, Akeo Hagiwara, Kimihiko Osaki, Takayuki Ohyama, Sakakibara T, Akira Sakuyama, Masaharu Ohgaki, Imanishi T, Norimasa Watanabe, Junya Yamazaki
    Abstract:

    The therapeutic effects of the new anti-angiogenesis factor TNP-470 were examined against Carcinomatous Peritonitis in mice. In the first experiment using Carcinomatous Peritonitis caused by i.p. inoculation of 106 M5076 tumor cells, TNP-470 solution was injected i.p. in a bolus of 50 mg/kg body wei

  • Therapy of Carcinomatous Peritonitis by the angiogenesis inhibitor TNP-470 in mice: analysis of timing and doses for intraperitoneal administration
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995
    Co-Authors: Hiroyuki Tsujimoto, Kimihiko Osaki, Sakakibara T, Masaharu Ohgaki, Imanishi T, Masataka Shimotsuma, Shirasu M, Ohyama T, Yamasaki J, Hagiwara A
    Abstract:

    In order to perform therapy for Carcinomatous Peritonitis by a new angiogenesis inhibitor, TNP-470, we investigated the effective timing and the optimal doses for intraperitoneal administration using two mice models. In both Carcinomatous Peritonitis models caused by M 5076 tumor and B 16 melanoma, the early administration of TNP-470 within one week after tumor inoculation extended the survival times of the mice receiving the drugs, whereas the administration of TNP-470 one week or later after inoculation did not affect the survival time. However, there were significant differences in the effective therapeutic doses of TNP-470 between the two models. It is important to select the best timing and doses for intraperitoneal administration of TNP-470 based on the state of angiogenesis and the sensitivity of the tumor tissues to TNP-470.

  • Therapeutic efficiency of an angiogenesis inhibitor, TNP-470, against Carcinomatous Peritonitis in rodents
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993
    Co-Authors: Ozaki K, Hiroyuki Tsujimoto, Takashi Takahashi, Hagiwara A, Masataka Shimotsuma, Chouhei Sakakura, Sadayuki Sasaki, Shirasu M, Oyama T, Sakakibara T
    Abstract:

    TNP-470, an analog of fumagillin, is one of the new angiogenesis inhibitors. Five days after an intraperitoneal inoculation of 10(7) cells of Walker 256 carcinosarcoma to SD rats, TNP-470 was injected intraperitoneally in the form of TNP aqueous solution or TNP-oil solution. Mean survival time of rats given TNP-oil solution or TNP aqueous solution was statistically prolonged, compared with that of the control rats. Our results showed that TNP-470 is an effective therapeutic drug for Carcinomatous Peritonitis.

Akeo Hagiwara - One of the best experts on this subject based on the ideXlab platform.

  • The influences of a novel anti-adhesion device, thermally cross-linked gelatin film on peritoneal dissemination of tumor cells: The in vitro and in vivo experiments using murine Carcinomatous Peritonitis models.
    Journal of biomedical materials research. Part B Applied biomaterials, 2017
    Co-Authors: Hiroe Miyamoto, Hiroyuki Tsujimoto, Tsunehito Horii, Yuki Ozamoto, Joe Ueda, Toshitaka Takagi, Naoto Saitoh, Akeo Hagiwara
    Abstract:

    To create anti-adhesive materials to be more effective and safer, we developed a thermally cross-linked gelatin film that showed superior anti-adhesive effects with excellent peritoneal regeneration. However, it may act as a convenient scaffold for tumor cell growth, thereby accelerating peritoneal dissemination when used in surgery for abdominal tumors. In this study, we tried to clarify this issue using mouse Carcinomatous Peritonitis models. First, we examined the in vitro tumor cell growth of mouse B16 melanoma or Colon26 cells on the gelatin film or the conventional hyarulonate/carboxymethylcellulose film. Tumor cell growth on each film was significantly lower than that of the control (no film). Next, we conducted the following in vivo experiments: After the parietal peritoneum was partially removed and covered with each film or without any film, mice were inoculated intraperitoneally with B16 melanoma or Colon26/Nluc cells expressing NanoLuc luciferase gene. At 7 days after the operation, we measured the weight of B16 melanoma tumors or the NanoLuc activity of Colon26/Nluc cells using in vivo imaging at the injured sites. There were no significant differences in the weight of the tumors and the NanoLuc activity among the three groups. We also observed the survival time of mice receiving the same operation and treatments. There was no significant difference in the survival time among the three groups. These results suggest that the gelatin film will likely not accelerate peritoneal dissemination as a convenient scaffold for tumor cell growth when used in surgery for abdominal tumors. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 2122-2130, 2018.

  • Treatment of postoperative recurrence of digestive cancers: Peritonitis carcinomatosa
    Nihon Geka Gakkai zasshi, 1999
    Co-Authors: Toshiharu Yamaguchi, Akeo Hagiwara, Chouhei Sakakura, Shirasu M, Takahashi T, Kiyoshi Sawai, Taniguchi H, Kitamura K, Eigo Otsuji, Okamoto K
    Abstract:

    Carcinomatous Peritonitis is the most frequent type of recurrence observed after surgery for cancer of the digestive tract. Most patients with Carcinomatous Peritonitis present with bowel obstruction and/or ascites. Surgical treatment including colostomy and intestinal anastomosis and chemotherapy have been attempted in patients with Carcinomatous Peritonitis, although the results have not been satisfactory. New drug delivery systems, such as mitomycin C-adsorbed charcoal, anticancer drugs entrapped in microspheres, and immunoconjugates composed of anticancer drugs and antibodies, will be powerful new tools for the treatment of metastatic cancer.

  • Therapeutic effects of the angiogenesis inhibitor TNP-470 against Carcinomatous Peritonitis in mice.
    Anti-cancer drugs, 1995
    Co-Authors: Hiroyuki Tsujimoto, Akeo Hagiwara, Kimihiko Osaki, Takayuki Ohyama, Sakakibara T, Akira Sakuyama, Masaharu Ohgaki, Imanishi T, Norimasa Watanabe, Junya Yamazaki
    Abstract:

    The therapeutic effects of the new anti-angiogenesis factor TNP-470 were examined against Carcinomatous Peritonitis in mice. In the first experiment using Carcinomatous Peritonitis caused by i.p. inoculation of 106 M5076 tumor cells, TNP-470 solution was injected i.p. in a bolus of 50 mg/kg body wei

Sakakibara T - One of the best experts on this subject based on the ideXlab platform.

  • Therapeutic effects of the angiogenesis inhibitor TNP-470 against Carcinomatous Peritonitis in mice.
    Anti-cancer drugs, 1995
    Co-Authors: Hiroyuki Tsujimoto, Akeo Hagiwara, Kimihiko Osaki, Takayuki Ohyama, Sakakibara T, Akira Sakuyama, Masaharu Ohgaki, Imanishi T, Norimasa Watanabe, Junya Yamazaki
    Abstract:

    The therapeutic effects of the new anti-angiogenesis factor TNP-470 were examined against Carcinomatous Peritonitis in mice. In the first experiment using Carcinomatous Peritonitis caused by i.p. inoculation of 106 M5076 tumor cells, TNP-470 solution was injected i.p. in a bolus of 50 mg/kg body wei

  • Therapy of Carcinomatous Peritonitis by the angiogenesis inhibitor TNP-470 in mice: analysis of timing and doses for intraperitoneal administration
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995
    Co-Authors: Hiroyuki Tsujimoto, Kimihiko Osaki, Sakakibara T, Masaharu Ohgaki, Imanishi T, Masataka Shimotsuma, Shirasu M, Ohyama T, Yamasaki J, Hagiwara A
    Abstract:

    In order to perform therapy for Carcinomatous Peritonitis by a new angiogenesis inhibitor, TNP-470, we investigated the effective timing and the optimal doses for intraperitoneal administration using two mice models. In both Carcinomatous Peritonitis models caused by M 5076 tumor and B 16 melanoma, the early administration of TNP-470 within one week after tumor inoculation extended the survival times of the mice receiving the drugs, whereas the administration of TNP-470 one week or later after inoculation did not affect the survival time. However, there were significant differences in the effective therapeutic doses of TNP-470 between the two models. It is important to select the best timing and doses for intraperitoneal administration of TNP-470 based on the state of angiogenesis and the sensitivity of the tumor tissues to TNP-470.

  • Therapeutic efficiency of an angiogenesis inhibitor, TNP-470, against Carcinomatous Peritonitis in rodents
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993
    Co-Authors: Ozaki K, Hiroyuki Tsujimoto, Takashi Takahashi, Hagiwara A, Masataka Shimotsuma, Chouhei Sakakura, Sadayuki Sasaki, Shirasu M, Oyama T, Sakakibara T
    Abstract:

    TNP-470, an analog of fumagillin, is one of the new angiogenesis inhibitors. Five days after an intraperitoneal inoculation of 10(7) cells of Walker 256 carcinosarcoma to SD rats, TNP-470 was injected intraperitoneally in the form of TNP aqueous solution or TNP-oil solution. Mean survival time of rats given TNP-oil solution or TNP aqueous solution was statistically prolonged, compared with that of the control rats. Our results showed that TNP-470 is an effective therapeutic drug for Carcinomatous Peritonitis.

A. Chakrabarty - One of the best experts on this subject based on the ideXlab platform.

  • Nijmegen breakage syndrome: a neuropathological study
    Neuropathology and Applied Neurobiology, 2002
    Co-Authors: Martin Lammens, J. A. P. Hiel, F. J. M. Gabreëls, C. M. R. Weemaes, A. Chakrabarty
    Abstract:

    Introduction:  Nijmegen breakage syndrome (NBS) is an autosomal recessive disorder, which belongs to the DNA repair disorders. It is characterized by microcephaly, typical facial appearance, immunodeficiency, X-ray hypersensitivity and predisposition of cancer. Material and methods:  Neuropathological examination of the brain was performed on a male NBS patient with moderate mental retardation, who was successfully treated for non-Hodgkin's lymphoma at the age of 19 years. He died at the age of 31 years as a result of Carcinomatous Peritonitis. Results:  Severe microcephaly (> 3SD

Hagiwara A - One of the best experts on this subject based on the ideXlab platform.

  • Therapy of Carcinomatous Peritonitis by the angiogenesis inhibitor TNP-470 in mice: analysis of timing and doses for intraperitoneal administration
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995
    Co-Authors: Hiroyuki Tsujimoto, Kimihiko Osaki, Sakakibara T, Masaharu Ohgaki, Imanishi T, Masataka Shimotsuma, Shirasu M, Ohyama T, Yamasaki J, Hagiwara A
    Abstract:

    In order to perform therapy for Carcinomatous Peritonitis by a new angiogenesis inhibitor, TNP-470, we investigated the effective timing and the optimal doses for intraperitoneal administration using two mice models. In both Carcinomatous Peritonitis models caused by M 5076 tumor and B 16 melanoma, the early administration of TNP-470 within one week after tumor inoculation extended the survival times of the mice receiving the drugs, whereas the administration of TNP-470 one week or later after inoculation did not affect the survival time. However, there were significant differences in the effective therapeutic doses of TNP-470 between the two models. It is important to select the best timing and doses for intraperitoneal administration of TNP-470 based on the state of angiogenesis and the sensitivity of the tumor tissues to TNP-470.

  • Therapeutic efficiency of an angiogenesis inhibitor, TNP-470, against Carcinomatous Peritonitis in rodents
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993
    Co-Authors: Ozaki K, Hiroyuki Tsujimoto, Takashi Takahashi, Hagiwara A, Masataka Shimotsuma, Chouhei Sakakura, Sadayuki Sasaki, Shirasu M, Oyama T, Sakakibara T
    Abstract:

    TNP-470, an analog of fumagillin, is one of the new angiogenesis inhibitors. Five days after an intraperitoneal inoculation of 10(7) cells of Walker 256 carcinosarcoma to SD rats, TNP-470 was injected intraperitoneally in the form of TNP aqueous solution or TNP-oil solution. Mean survival time of rats given TNP-oil solution or TNP aqueous solution was statistically prolonged, compared with that of the control rats. Our results showed that TNP-470 is an effective therapeutic drug for Carcinomatous Peritonitis.